Teva Upbeat On Risperidone Results

Collaborating With MedinCell On Long-Acting Injectable Version

 
• By Dave Wallace

Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.

Risperidone Molecule
Teva and MedinCell have announced positive results for their LAI risperidone • Source: Shutterstock

More from Value Added Medicines

More from Products